“Second-Line Treatment With Axitinib: An Effective and Well-Tolerated Weapon in the Therapeutic Sequence of Clear Cell Renal Cell Carcinoma”. 2015. Working Paper of Public Health 4 (1). https://doi.org/10.4081/wpph.2015.6697.